Medicus Pharma Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MDCX | JNJ | BIIB | MRK | BMY | SNGX | |
|---|---|---|---|---|---|---|
| Market cap | 5.13M | 635.56B | 33.90B | 358.85B | 117.62B | 7.65M |
| P/E (TTM) | — | 30.8 | 41.4 | 115.4 | 12.4 | — |
| Forward P/E | -0.1 | 21.3 | 13.9 | 15.6 | 8.7 | -1.4 |
| Price/book | -123.4 | 7.5 | 1.8 | 8.6 | 5.3 | 1.1 |
| Dividend yield | — | 2.03% | — | 2.34% | 4.38% | — |
| 1-year change | −96.99% | +38.19% | +57.88% | +71.72% | +31.46% | −78.53% |
| Today | −22.26% | +0.88% | +1.64% | −0.10% | −2.60% | −3.27% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All MDCX news ›Medicus Pharma Shifts Focus to Oncology Amid Stock Volatility
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is concentrating its drug-development investments on targeted cancer therapies while pursuing partnerships to limit future financing requirements, a strategic shift that follows…
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a…
Medicus Pharma seeks FDA alignment on streamlined Phase 2b/3 Teverelix study
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company’s submission of an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration (FDA) for Teverelix®, its…
ICYMI: Medicus Seeks FDA Path to Cut Teverelix Trial by 60%
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has proposed a redesigned late-stage development program for its prostate cancer drug Teverelix that could reduce planned enrollment by about 60% while positioning the asset for…
Small cap wrap: Medicus Pharma, BioHarvest, Ondine...
FireFly Metals Ltd (ASX:FFM, TSX:FFM, OTC:FFMFF) has raised almost A$5 million through its Share Purchase Plan (SPP), adding to the approximately A$180 million secured through its recent equity raising and further strengthening funding for…
Medicus Pharma Ltd. Submits Optimized Seamless Phase 2B/3 Registration-Intent Protocol to FDA for Teverelix in Advanced Prostate Cancer
marketscreener.com had submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S Food and Drug Administration (?FDA?) for Teverelix®, its investigational, next generation, long-acting GnRH antagonist, in advanced…
Medicus Pharma Narrows SkinJect Focus To Gorlin Syndrome, Drops Sporadic BCC Program
Medicus Pharma Ltd. (MDCX) announced that it will focus future internally sponsored clinical development of SkinJect exclusively on patients with Gorlin syndrome and multiple basal cell carcinoma (BCC) lesions, while concluding further…
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a transformative agreement with Pfizer that significantly strengthens the company’s position in precision oncology and provides key resources to advance its…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
mychesco.com3
-
proactiveinvestors.com3
-
aol.com1
-
rttnews.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.